Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Hematologic Oncology Update
00:00
Choosing between acalabrutinib and zanubrutinib
She contrasts acalabrutinib and zanubrutinib dosing, cardiovascular profiles, and practical insurance influences.
Play episode from 17:17
Transcript
